LSTA

#3589
Lisata Therapeutics, Inc. Common Stock
4.10
-6.82%
セクター:
ベース:
利益通貨:
日中レンジ
4.10
4.10
1年のレンジ
1.81
4.89
1日の変化
-6.82%
月次変化
-11.26%
6か月変化
+67.35%
1年の変化
+77.49%
以前の終値
4.40
Open
4.10
Bid
Ask
Low
4.10
High
4.10
ボリューム
11
Open full chart

Financials

Overview 明細書 Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

ニュース